ENTPD1 (CD39) Expression Inhibits UVR-Induced DNA Damage Repair through Purinergic Signaling and Is Associated with Metastasis in Human Cutaneous Squamous Cell Carcinoma.

Adenosine / physiology Apyrase / analysis Carcinoma, Squamous Cell / etiology DNA Damage DNA Repair Forkhead Transcription Factors / analysis Humans Interleukin-27 / physiology Memory T Cells / immunology Neoplasm Metastasis Programmed Cell Death 1 Receptor / analysis Skin Neoplasms / etiology Ultraviolet Rays / adverse effects

Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
10 2021
Historique:
received: 13 11 2020
revised: 21 01 2021
accepted: 07 02 2021
pubmed: 14 4 2021
medline: 15 12 2021
entrez: 13 4 2021
Statut: ppublish

Résumé

UVR and immunosuppression are major risk factors for cutaneous squamous cell carcinoma (cSCC). Regulatory T cells promote cSCC carcinogenesis, and in other solid tumors, infiltrating regulatory T cells and CD8

Identifiants

DOI: 10.1016/j.jid.2021.02.753 PMID: 33848530
pubmed: 33848530
pii: S0022-202X(21)01118-0
doi: 10.1016/j.jid.2021.02.753
pii:
doi:

Substances chimiques

FOXP3 protein, human 0
Forkhead Transcription Factors 0
Interleukin-27 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Apyrase EC 3.6.1.5
ENTPD1 protein, human EC 3.6.1.5
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2509-2520

Subventions

Organisme : Wellcome Trust
ID : 100683/Z/12/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Melodi Javid Whitley (MJ)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.

Jutamas Suwanpradid (J)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.

Chester Lai (C)

Dermatopharmacology, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Department of Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Simon W Jiang (SW)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.

Jonathan L Cook (JL)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.

Daniel E Zelac (DE)

Department of Dermatology and Mohs Surgery, Scripps Clinic, La Jolla, California, USA.

Ross Rudolph (R)

Division of Plastic Surgery, Scripps Clinic, San Diego, California, USA; Division of Plastic Surgery, University of California San Diego, San Diego, California, USA.

David L Corcoran (DL)

Center for Genomic and Computational Biology, Duke University School of Medicine, Durham, North Carolina, USA; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.

Simone Degan (S)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.

Ivan Spasojevic (I)

Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; PK/PD Core Lab, Duke Cancer Institute, Durham, North Carolina, USA.

Howard Levinson (H)

Division of Plastic, Maxillofacial, and Oral Surgery, Duke Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.

Detlev Erdmann (D)

Division of Plastic, Maxillofacial, and Oral Surgery, Duke Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.

Claire Reid (C)

Dermatopharmacology, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Department of Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Jennifer Y Zhang (JY)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA; Pinnell Center for Investigative Dermatology, Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Simon C Robson (SC)

Department of Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, Massachusetts, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA.

Eugene Healy (E)

Dermatopharmacology, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Department of Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

Wendy L Havran (WL)

Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, California, USA.

Amanda S MacLeod (AS)

Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA; Pinnell Center for Investigative Dermatology, Department of Duke Dermatology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA; Department of Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: Amanda.MacLeod@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Adénosine › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Acid anhydride hydrolases › Apyrase › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs épidermoïdes › Carcinome épidermoïde › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Phénomènes génétiques › Réparation de l'ADN › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif hélice ailée › Facteurs de transcription Forkhead › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-27 › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Cellules T mémoire › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › ENTPD1 (CD39) Expression Inhibits UVR-Induced...
questionsmedicales.fr › Environnement et santé publique › Environnement › Concepts météorologiques › Atmosphère › Temps (météorologie) › Lumière du soleil › Rayons ultraviolets › ENTPD1 (CD39) Expression Inhibits UVR-Induced...